CRED 8 Presentations
01/07/2024
Types of Application
• Biosimilars and generics/hybrids: •
Mandatory scope of application (Reference product/comparator is a centrally approved MA) • Optional scope (reference / comparator product has national/MRP/DCP) • Advanced therapy Medicinal Products (ATMPs): • Complex therapies; seek a classification in advance of applying for MAA • Different Regulatory Framework and EMA Pre-submission Q&As: • Generics/hybrids/biosimilars/ATMPs have different legal basis and are regulated by additional sets of regulations and guidance's e.g. ATMP Regulation 1397/2007 • Different dossier requirements e.g. biosimilars: dossier based on totality of comparability exercise data e.g. step-wise approach for biosimilars to show no clinically meaningful differences (CMC heavy, less clinical data)
The Organisation for Professionals in Regulatory Affairs
39
Recap
Content and Preparation of eCTD
Reference: EudraLex Volume 2:https://ec.europa.eu/health/documents/eudralex/vol-2_en
The Organisation for Professionals in Regulatory Affairs
40
Made with FlippingBook Ebook Creator